FI110993B - Förfarande för tillverkning av polysakkarid-proteinkonjugat av B-gruppens streptokock typer II och V - Google Patents

Förfarande för tillverkning av polysakkarid-proteinkonjugat av B-gruppens streptokock typer II och V Download PDF

Info

Publication number
FI110993B
FI110993B FI951412A FI951412A FI110993B FI 110993 B FI110993 B FI 110993B FI 951412 A FI951412 A FI 951412A FI 951412 A FI951412 A FI 951412A FI 110993 B FI110993 B FI 110993B
Authority
FI
Finland
Prior art keywords
type
polysaccharide
gbs
vaccine
protein
Prior art date
Application number
FI951412A
Other languages
English (en)
Finnish (fi)
Other versions
FI951412A (sv
FI951412A0 (sv
Inventor
Harold J Jennings
Dennis L Kasper
Original Assignee
Brigham & Womens Hospital
Ca Nat Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26823688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI110993(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US1993/009056 external-priority patent/WO1994006467A1/en
Application filed by Brigham & Womens Hospital, Ca Nat Research Council filed Critical Brigham & Womens Hospital
Publication of FI951412A0 publication Critical patent/FI951412A0/sv
Publication of FI951412A publication Critical patent/FI951412A/sv
Application granted granted Critical
Publication of FI110993B publication Critical patent/FI110993B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/813—Carrier is a saccharide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Claims (6)

1. Förfarande för tillverkning av en antigen konjugatmolekyl av kapselpolysacka-rid av B-gruppens streptokock typ II eller typ V och protein, kännetecknat av att * 5 (a) kapselpolysackarid av B-gruppens streptokock typ II eller typ V oxideras till- räckligt med perjodat för att bilda en aldehydgrupp i tvä eller flera terminala sial-syrarester anslutna tili polysackaridens stam; (b) den oxiderade kapselpolysackariden av B-gruppens streptokock typ II eller typ V ansluts tili ett protein via reducerande aminering för att ästadkomma en sekundär 10 aminbindning mellan kapselpolysackariden och proteinet.
2. Förfarande enligt patentkrav 1, kännetecknat av att ca 5-50 %, företrädesvis ca 5-35 %, heist ca 5-10 %, av varje polysackarids sialsyrarester oxideras för att bilda aldehydgrupper som förmär anslutas till protein. 15
3. Förfarande enligt patentkrav 2, kännetecknat av att polysackariden är GBS typ II och att ca 7 % av varje polysackarids sialsyrarester oxideras för att bilda aldehydgrupper som förmär anslutas till protein. 20
4. Förfarande enligt patentkrav 1, kännetecknat av att ca 5-50 %, företrädesvis ca 5-25 %, heist ca 5-10 %, av varje polysackarids sialsyrarester binds kovalent tili protein.
5. Förfarande enligt patentkrav 4, kännetecknat av att polysackariden är GBS . · 25 typ II och att ca 5 % av varje polysackarids sialsyrarester binds kovalent till protein.
6. Förfarande enligt patentkrav 1, kännetecknat av att polysackariden är GBS typ V och att ca 25 % av varje polysackarids terminala sialsyrarester binds kovalent till protein. 30 # · * · 4
FI951412A 1992-09-24 1995-03-24 Förfarande för tillverkning av polysakkarid-proteinkonjugat av B-gruppens streptokock typer II och V FI110993B (sv)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US94997092A 1992-09-24 1992-09-24
US94997092 1992-09-24
US12555693A 1993-09-23 1993-09-23
US12555693 1993-09-23
PCT/US1993/009056 WO1994006467A1 (en) 1992-09-24 1993-09-24 Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines
US9309056 1993-09-24

Publications (3)

Publication Number Publication Date
FI951412A0 FI951412A0 (sv) 1995-03-24
FI951412A FI951412A (sv) 1995-05-24
FI110993B true FI110993B (sv) 2003-05-15

Family

ID=26823688

Family Applications (1)

Application Number Title Priority Date Filing Date
FI951412A FI110993B (sv) 1992-09-24 1995-03-24 Förfarande för tillverkning av polysakkarid-proteinkonjugat av B-gruppens streptokock typer II och V

Country Status (16)

Country Link
US (2) US5795580A (sv)
EP (1) EP0667787B1 (sv)
JP (3) JP4163251B2 (sv)
KR (1) KR100293017B1 (sv)
AT (1) ATE203167T1 (sv)
AU (1) AU690525B2 (sv)
CA (1) CA2145397C (sv)
DE (1) DE69330464T2 (sv)
DK (1) DK0667787T3 (sv)
ES (1) ES2160601T3 (sv)
FI (1) FI110993B (sv)
GR (1) GR3036928T3 (sv)
IL (1) IL107103A (sv)
NO (2) NO319569B1 (sv)
NZ (2) NZ299249A (sv)
PT (1) PT667787E (sv)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69719677T2 (de) * 1996-11-18 2003-09-18 Japan Storage Battery Co. Ltd., Kyoto Positivelektrode für Lithiumbatterie und Lithiumbatterie
JP2002502830A (ja) * 1998-02-05 2002-01-29 ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン タンパク質−多糖コンジュゲートおよびワクチンの製造中に遊離タンパク質を除去するための、接近が制限された媒介材料を用いる簡素化された方法
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
EP1810978B1 (en) 2000-08-08 2013-02-13 St. Jude Children's Research Hospital Group B streptococcus polypeptides nucleic acids and therapeutic composition and vaccines thereof
SV2003000753A (es) * 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
US20030185858A1 (en) * 2001-08-15 2003-10-02 Birkett Ashley J. Immunogenic HBc chimer particles stabilized with an N-terminal cysteine
US7534442B2 (en) * 2001-08-21 2009-05-19 The Brigham And Women's Hospital, Inc. Immunogenic compositions comprising covalently bound polysaccharides, antigen, and bacterial toxoid
AU2003257003A1 (en) * 2002-07-30 2004-02-16 Baxter Healthcare S.A. Chimeric multivalent polysaccharide conjugate vaccines
EP1638581A2 (en) * 2003-03-31 2006-03-29 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
CA2530363C (en) * 2003-06-23 2013-05-07 Baxter International Inc. Carrier proteins for vaccines
WO2006050341A2 (en) * 2004-11-01 2006-05-11 The Brigham And Women's Hospital, Inc. Modified streptococcal polysaccharides and uses thereof
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
US8206726B2 (en) * 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
GB201101665D0 (en) * 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2013009945A1 (en) 2011-07-12 2013-01-17 The Brigham And Women's Hospital, Inc. Lipid-containing psa compositions, methods of isolation and methods of use thereof
KR20150073943A (ko) 2012-10-03 2015-07-01 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
MY182282A (en) * 2015-05-04 2021-01-18 Pfizer Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
WO2017031431A1 (en) 2015-08-19 2017-02-23 President And Fellows Of Harvard College Lipidated psa compositions and methods
EP3484441A4 (en) 2016-07-15 2020-03-18 President and Fellows of Harvard College GLYCOLIPID COMPOSITIONS AND METHODS OF USE
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
CN113966234A (zh) * 2019-05-10 2022-01-21 葛兰素史克生物有限公司 缀合物的产生

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4207414A (en) * 1978-08-16 1980-06-10 President And Fellows Of Harvard College Polysaccharide antigens
US4324887A (en) * 1978-08-16 1982-04-13 President And Fellows Of Harvard College Type II group B Streptococci polysaccharide
IE51174B1 (en) * 1980-04-14 1986-10-29 Merck & Co Inc Group b streptococcal capsular polysaccharides
US4438261A (en) * 1980-05-19 1984-03-20 Riker Laboratories, Inc. Anticoagulant substance
US4367222A (en) * 1980-06-09 1983-01-04 President And Fellows Of Harvard College Immune globulin specific to Group B streptococci
US4367223A (en) * 1980-06-09 1983-01-04 President And Fellows Of Harvard College Vaccine against Group B streptococci
US4356263A (en) * 1980-06-09 1982-10-26 President And Fellows Of Harvard College Method of making a polysaccharide vaccine
US4367221A (en) * 1980-06-09 1983-01-04 President And Fellows Of Harvard College Immunization against Group B streptococci
US4284537A (en) * 1980-07-03 1981-08-18 The United States Of America As Represented By The Department Of Health And Human Services Conjugate of streptococcal M protein peptide vaccine
US4425330A (en) * 1981-05-20 1984-01-10 Cornell Research Foundation, Inc. Bovine mastitis vaccine and method for detecting efficacy thereof
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4757134A (en) * 1982-12-02 1988-07-12 The Rockefeller University IgA binding protein
ATE70308T1 (de) * 1984-09-12 1991-12-15 Chiron Corp Hybridpartikel-immunogene.
FR2581877B1 (fr) * 1985-05-14 1987-12-18 Louvain Universite Catholique Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries
US5302386A (en) * 1986-04-16 1994-04-12 Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines and methods of manufacture
DE3750139T2 (de) * 1986-04-16 1994-10-06 Brigham & Womens Hospital Bakterielle antigene, antikörper, impfstoffe und deren herstellung.
WO1989000583A1 (en) * 1987-07-17 1989-01-26 Xoma Corporation Improved immunotoxin therapies utilizing purified ricin a-chain species
IL95578A (en) * 1989-09-15 1998-08-16 Gen Hospital Corp A vaccine made from polysaccharide and protein
EP0504202B1 (en) * 1989-12-14 1995-05-03 National Research Council Of Canada Improved meningococcal polysaccharide conjugate vaccine
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.

Also Published As

Publication number Publication date
ATE203167T1 (de) 2001-08-15
JP4308174B2 (ja) 2009-08-05
JP2005306884A (ja) 2005-11-04
JP4163251B2 (ja) 2008-10-08
DE69330464T2 (de) 2001-11-08
DE69330464D1 (en) 2001-08-23
IL107103A (en) 2001-03-19
NZ248766A (en) 1996-11-26
AU5137893A (en) 1994-04-12
CA2145397C (en) 2007-10-30
DK0667787T3 (da) 2001-10-29
US5993825A (en) 1999-11-30
NO319569B1 (no) 2005-08-29
NO951109L (no) 1995-05-22
PT667787E (pt) 2001-10-31
KR950703361A (ko) 1995-09-20
NO951109D0 (no) 1995-03-23
IL107103A0 (en) 1994-08-26
JPH08501563A (ja) 1996-02-20
NZ299249A (en) 2000-08-25
CA2145397A1 (en) 1994-03-31
JP2009132727A (ja) 2009-06-18
EP0667787B1 (en) 2001-07-18
EP0667787A1 (en) 1995-08-23
ES2160601T3 (es) 2001-11-16
FI951412A (sv) 1995-05-24
US5795580A (en) 1998-08-18
FI951412A0 (sv) 1995-03-24
KR100293017B1 (ko) 2001-09-17
AU690525B2 (en) 1998-04-30
GR3036928T3 (en) 2002-01-31
NO951152D0 (no) 1995-03-24

Similar Documents

Publication Publication Date Title
FI110993B (sv) Förfarande för tillverkning av polysakkarid-proteinkonjugat av B-gruppens streptokock typer II och V
Paoletti et al. Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine
Paoletti et al. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine
Wessels et al. Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine
US7332173B2 (en) Group A streptococcal polysaccharide immunogenic compositions and methods
JP2736248B2 (ja) 莢膜ポリマーフラグメントの製造方法
US4673574A (en) Immunogenic conjugates
US4761283A (en) Immunogenic conjugates
EP0598818B1 (en) Escherichia coli o-polysaccharide-protein conjugate vaccine
US5843461A (en) Group B streptococcus type II polysaccharide-tetanus toxoid conjugate vaccines
EA006602B1 (ru) Применение стафилококковых и энтерококковых вакцин для защиты иммунокомпромиссного субъекта от бактериальных инфекций
CA2101648C (en) Polysaccharide-protein conjugates
US4762713A (en) Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers